Bramante Biologics recently launched!

‍

^{"Modern manufacturing for protein therapeutics"}

‍

^{TL;DR: Bramante Biologics manufactures pharmaceutical drugs faster than current methods and in the USA. They are building microfactories that can handle the upcoming wave of AI-designed drugs and safeguard against biothreats.}

‍

Launch Video

‍

Founded by Scott Stankey & Michael Magaraci‍

The team loves biomanufacturing. Together, they built Protein Evolution, an industrial biotech company that turned plastic waste into new textile fibers. Scott is ex-McKinsey and a Yale mathematician (he loves a good cost model almost as much as he loves America). Mike earned his PhD in Bioengineering from Penn after completing Penn’s M&T program in undergrad (he builds DNA, software, and bioreactors).

‍

The Problem

America is at risk of ceding leadership in advanced biomanufacturing to China.

• Drug manufacturing is moving to China; 79% of US biotech and pharma companies already have at least one contract with a Chinese firm, primarily because they are faster.
• China is investing billions in biotech; one third of new compounds licensed by US pharma are now discovered and manufactured in China, up from almost none five years ago.
• Over-reliance on foreign biomanufacturing is a national-security risk; agile, on-shore manufacturing is critical to protect their nation against future biothreats.

‍

Bramante's Solution

A contract development and manufacturing organization (CDMO) for advanced drugs, rebuilt from the ground up to address the future of America’s biomanufacturing needs.

• Faster biomanufacturing; Their platform leverages advanced methods to accelerate production timelines and de-risk scale-up.
• Modular container factories; Their form factor is a standard shipping container that can be brought up to operation in roughly two weeks and shipped where it is needed.
• Supply-chain independence; by vertically integrating and manufacturing critical equipment in-house, they secure production against global disruptions.

‍

Why It Matters

• Drugs can be developed faster; shorter production cycles move life-saving drugs from the lab to the clinic up to a year sooner.
• More drugs can be developed; they will be able to manufacture the thousands of low-volume, personalized biologics that will be designed by AI.
• Strengthening US autonomy; rapid-deploy, U.S.-based capacity protects the nation from supply shocks, geopolitical turbulence, and potential bioweapons.

‍

Learn More

^‍

^{🌐 Visit www.bramantebio.com to learn more.}

‍

^{🤝 Please reach out if you work in drug development, work at a CDMO, or have experience working with or at the FDA.}

‍

^{👣 Follow Bramante Biologics on LinkedIn.}

‍